Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections

Antiviral Research

Volumn 37, Issue 1, 1998, Pages 1-16

  De Jong, M D ^a   Boucher, C A B ^b   Danner, S A ^a   Gazzard, B ^c   Griffiths, P D ^d   Katlama, C ^e   Lange, J M A ^a   Richman, D D ^f   Vella, S ^g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE; CIDOFOVIR; DIDANOSINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INTERFERON; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE ANALOG; RIBAVIRIN; RITONAVIR; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

CONFERENCE PAPER; HEPATITIS B VIRUS; HEPATITIS VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORGANIZATION; PATIENT CARE; PRIORITY JOURNAL; SYMPOSIUM;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VIRAL LOAD;

CUCUMBER MOSAIC VIRUS; HEPATITIS B VIRUS; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031975645     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00059-4     Document Type: Conference Paper

References (80)

1. Autran, B., Carcelain, G., Li, T.S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debre, P., Leibowitch, J., 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116.
2. Baldanti, F., Underwood, M.R., Stanat, S.C., Biron, K.K., Chou, S., Sarasini, A., Silini, E., Gerna, G., 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 170, 1390-1395.
3. Bartholomew, M.M., Jansen, R.W., Jeffers, L.J., Reddy, K.R., Johnson, L.C., Bunzendahl, H., Condreay, L.D., Tzakis, A.G., Schiff, E.R., Brown, N.A., 1997. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349, 20-22.
4. Benhamou, Y., Dohin, E., Lunel-Fabiani, F., Poynard, T., Huraux, J.M., Katlama, C., Opolon, P., Gentilini, M., 1995. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345, 396-397.
5. Boivin, G., Chou, S., Quirk, M.R., Erice, A., Jordan, M.C., 1996. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leucocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173, 523-528.
6. Bowen, E.F., Wilson, P., Cope, A., Sabin, C., Griffiths, P., Davey, C., Johnson, M., Emery, V., 1996. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10, 1515-1520.
7. Bowen, E.F., Sabin, C.A., Wilson, P., Griffiths, P.D., Davey, C.C., Johnson, M.A., Emery, V.C., 1997. Cytomegalovirus (CMV) viraemia detected by polymerase gene reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 11, 889-893.
8. Braconier, J.H., Paulsen, O., Engman, K., Widell, A., 1995. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand. J. Infect. Dis. 27, 325-329.
9. Brillanti, S., Garson, J., Foli, M., Whitby, K., Denville, R., Masci, C., Miglioli, M., Barbara, L., 1994. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812-817.
10. Brillanti, S., Miglioli, M., Barbara, L., 1995. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J. Hepatol. 23 (Suppl. 2), 13-15.
11. Brook, M.G., Karayiannis, P., Thomas, H.C., 1989. Which patients with chronic hepatitis B virus infection will respond to alfa-interferon therapy? A statistical analysis of predictive factors. Hepatology 10, 761-763.
12. Cavert, W., Notermans, D.W., Staskus, K., Wietgrefe, S.W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z.Q., Mills, R., McDade, H., Goudsmit, J., Danner, S.A., Haase, A.T., 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964.
13. Chemello, L., Cavaletto, L., Bernardinello, E., Guido, M., Pontisso, P., Alberti, A., 1995. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 23 (suppl. 2), 8-12.
14. Choi, S., Lagakos, S.W., Schooley, R.T., Volberding, P.A., 1993. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann. Intern. Med. 118, 674-680.
15. Chou, S., Erice, A., Jordan, M.C., Vercelotti, G.M., Michels, K.R., Talarico, C.L., Stanat, S.C., Biron, K.K., 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171, 576-583.
16. Chun, T.W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J.A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T.C., Kuo, Y.H., Brookmeyer, R., Zeiger, M.A., Barditch-Crovo, P., Siliciano, R.F., 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-187.
17. Clark, S.J., Saag, M.S., Decker, W.D., Campbell-Hill, S., Robertson, J.L., Veldkamp, P.J., Kappes, J.C., Hahn, B.H., Shaw, G.M., 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 324, 954-960.
18. Coffin, J.M., 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489.
19. Daar, E.S., Moudgil, T., Meyer, R.D., Ho, D.D., 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324, 961-964.
20. De Jong, M.D., Veenstra, J., Stlianakis, N.I., Schuurman, R., Lange, J.M.A., De Boer, R.J., Boucher, C.A.B., 1996. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load by zidovudine. Proc. Natl. Acad. Sci. U.S.A. 93, 5501-5505.
21. De Jong, M.D., Boucher, C.A.B., Cooper, D.A., Galasso, G.J., Gazzard, B., Lange, J.M.A., Montaner, J.S., Richman, D.D., Thomas, H.C., 1997. Summary of the II International consensus symposium on combined antiviral therapy and implications for future therapies. Antiviral. Res. 35, 65-82.
22. Dienstag, J.L., Perrillo, R.P., Schiff, E.R., Bartholomew, M., Vicary, C., Rubin, M., 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333, 1657-1661.
23. Dodt, K.K., Jacobsen, P.H., Hofmann, B., Meyer, C., Kolmos, H.J., Skinhoj, P., Norrild, B., Mathiesen, L., 1997. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 11, F21-F28.
24. Dunn, J.P. and Jabs, D.A., 1995. Cytomegalovirus retinitis in AIDS: natural history, diagnosis and treatment. In: Volberding, P., Jacobson, M.A. (Eds.), AIDS Clinical Review 1995/1996. New York: Marcel Dekker, pp. 99-129.
25. Einsele, H., Ehninger, G., Hebart, H., Wittkowski, K.M., Schuler, V., John, G., Mackes, P., Herter, M., Klingebiel, T., Loffler, J., 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86, 2815-2820.
26. Embretson, J., Zupancic, M., Ribas, J.L., Burke, A., Racz, P., Tenner-Racz, H., Haase, A.T., 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359-362.
27. Foudraine, N.A., Weverling, G.J., Van Gool, T., Roos, M.T.L., De Wolf, F., Koopmans, P.P., Van den Broek, P.J., Meenhorst, P.L., Van Leeuwen, R., Lange, J.M.A., Reiss, P., 1997. Improvement of chronic diarrhea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS, in press.
28. Fox, C.H., Tenner-Racz, K., Racz, P., Firpo, A., Pizzo, P.A., Fauci, A.S., 1991. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J. Infect. Dis. 164, 1051-1057.
29. Fox, J.C., Kidd, I.M., Griffiths, P.D., Sweny, P., Emery, V.C., 1995. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J. Gen. Virol. 76, 309-319.
30. Gerna, G., Parea, M., Percivalle, A., Zipeto, D., Silini, E., Barbarini, G., Milanesi, G., 1990. Human cytomegalovirus viraemia in HIV-1-seropositive patients at various clinical stages of infection. AIDS 4, 1027-1031.
31. Gerna, G., Zipeto, D., Parea, M., Revallo, M.G., Silini, E., Percivalle, E., Zavattoni, M., Grossi, P., Milanesi, G., 1991. Monitoring of human cytomegalovirus infection and ganciclovir treatment in heart transplant recipients by determination of viraemia, antigenaemia, and DNAemia. J. Infect. Dis. 164, 488-498.
32. Goodrich, J.M., Bowden, R.A., Fisher, L., Keller, C., Schoch, G., Meyers, J.D., 1993. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118, 173-178.
33. Grundy, J.E., Shanley, J.D., Griffiths, P.D., 1987. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet ii, 996-999.
34. Hansen, K.K., Richsten, A., Hofmann, B., Norrild, B., Olofsson, S., Mathiesen, L., 1994. Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus retinitis in AIDS. J. Infect. Dis. 170, 1271-1274.
35. Ho, D.D., 1995. Time to hit HIV: early and hard. N. Engl. J. Med. 333, 450-451.
36. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M., 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
37. Jouet, P., Roudot-Thoraval, F., Dhumeaux, D., Metreau, J.M., le groupe Francais pour l'etude du traitement des hepatites chroniques NANB/C, 1994. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patienst with non-A, non-B, C hepatitis. Gastroenterology 106, 686-690.
38. Kanai, K., Kako, M., Okamoto, H., 1992. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339, 1543.
39. Katzenstein, D.A., Hammer, S.M., Hughes, M.D., Gundacker, H., Jackson, J.B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., Merigan, T.C., Hirsch, M.S., 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335, 1091-1098.
40. Kelleher, A.D., Carr, A., Zaunders, J., Cooper, D.A., 1996. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor ritonavir. J. Infect. Dis. 173, 321-329.
41. Kidd, I.M., Fox, J.C., Pillay, D., Charman, H., Griffiths, P.D., Emery, V.C., 1993. Provision of prognostic information in immunocompromised patienst by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 56, 867-871.
42. Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., O'Malley, E.T., Harbeson, S.L., Rice, C.M., Marcko, M.A., Caron, P.R., Thomson, J.A., 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355.
43. Knox, K.K., Drobyski, W.R., Carrigan, D.R., 1991. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from marrow transplant patient. Lancet 2, 1292-1293.
44. Korba, E., 1995. In vitro evaluation of combination strategies against hepatitis B virus replication. Antiviral Res. 29, 49-51.
45. Kuppermann, B.D., Petty, J.G., Richman, D.D., Mathews, W.C., Fullerton, S.C., Rickman, L.S., Freeman, W.R., 1993. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am. J. Opthalmol. 115, 575-582.
46. Landry, M.L., Ferguson, D., 1993. Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with disease. J. Clin. Microbiol. 31, 2851-2856.
47. Lange, J.M.A., 1995. Triple combinations: present and future. AIDS Res. Hum. Retroviruses 10 (Suppl. 1), S77-S82.
48. Ling, R., Mutimer, D., Ahmed, M., Boxall, E.H., Elias, E., Dusheiko, G.M., Harrison, T.J., 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24, 711-713.
49. Mellors, J.W., Kingsley, L.A., Rinaldo, C.R., Todd, J.A., Hoo, B.S., Kukka, R.P., Gupta, P., 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122, 573-579.
50. Mellors, J.W., Rinaldo, C.R., Gupta, P., White, R.M., Todd, J.A., Kingsley, L.A., 1996. Prognosis in HIV-1 infection predicted by trhe quantity of virus in plasma. Science 272, 1167-1170.
51. Michael, N.L., Vahey, M., Burke, D.S., Redfield, R.R., 1992. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J. Virol. 66, 310-316.
52. Murphy, M., Armstrong, D., Sepkowitz, K.A., Ahkami, R.N., Myskowski, P.L., 1997. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 11, 261-262.
53. Nowak, M.A., Bonhoeffer, S., Hill, A.M., Boehme, R., Thomas, H.C., McDade, H., 1996. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. U.S.A. 93, 4398-4402.
54. O'Brien, W.A., Hartigan, P.M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M.S., Hamilton, J., 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334, 426-431.
55. Pantaleo, G., Graziosi, C., Butini, L., Pizzo, P.A., Schnittman, S.M., Kotler, D.P., Fauci, A.S., 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 88, 9838-9842.
56. Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., Montroni, M., Fox, C.H., Orenstein, J.M., Kotler, D.P., Fauci, A.S., 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358.
57. Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, H., Markowitz, M., Ho, D.D., 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191.
58. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., Ho, D.D., 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586.
59. Piatak, M.J., Saag, M.S., Yang, L.C., Clark, S.J., Kappes, J.C., Luk, H.C., Hahn, B.H., Shaw, G.M., Lifson, J.D., 1993. High levels of HIV-1 in plasma during all stages of infection detremined by competitive PCR. Science 259, 1749-1754.
60. Power, C., Nath, A., Aoki, F.Y., Del Bigio, M., 1997. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection. N. Engl. J. Med. 336, 661-662.
61. Rasmussen, L., Morris, S., Zipeto, D., Fessel, J., Wolitz, R., Dowling, A., 1995. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J. Infect. Dis. 171, 177-182.
62. Revallo, M.G., Percivalle, E., Zavattoni, M., Parea, M., Grossi, P., Gerna, G., 1989. Detection of human cytomegalovirus immediate early antigen in leucocytes as a marker of viraemia in immunocompromised patients. J. Med. Virol. 29, 88-93.
63. Rubin, R.H., 1991. Preemptive therapy in immunocompromised hosts. N. Engl. J. Med. 324, 1057-1059.
64. Salmon, D., Lacassin, F., Harzic, M., Leport, C., Perronne, C., Bricaire, F., Brun-Vezinet, F., Vilde, J.L., 1990. Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J. Med. Virol. 32, 160-163.
65. Sarasini, A.F., Baldantini, M., Furione, E., Percivalli, F., Brerra, R., Barbi, M., Gerna, G., 1995. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J. Med. Virol. 47, 237-244.
66. Schnittman, S.M., Greenhouse, J.J., Lane, H.C., Pierce, P.F., Fauci, A.S., 1991. Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing viral replication in all stages of disease. AIDS Res. Hum. Retroviruses 7, 361-367.
67. Schooley, R.T., Ramirez-Ronda, C., Lange, J.M.A., Cooper, D.A., Laville, J., Lefkowitz, L., Moore, M., Larder, B.A., St. Clair, M.H., Mulder, J.W., McKinnan, R., Pennington, K., Harrigan, P.R., Kinghorn, I., Steel, H., Rooney, J.F., 1996. Virologic and immunologic benefits of initial therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J. Infect. Dis. 173, 1354-1366.
68. Schuurman, R., Nijhuis, M., Van Leeuwen, R., Schipper, P., De Jong, D., Collis, P., Danner, S.A., Mulder, J., Loveday, C., Christopherson, C., Kwok, S., Sninsky, J., Boucher, C., 1995. Rapid changes in human immunodeficiency virus 1-RNA load and appearance of drug resistance mutations in persons treated with lamivudine. J. Infect. Dis. 171, 1411-1419.
69. Schvarcz, R., Yun, Z.B., Sonnerborg, A., Weiland, O., 1995. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46, 43-47.
70. Smith, I.L., Cherrington, J.M., Jiles, R.E., Fuller, M.D., Freeman, W.R., Spector, S.E., 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176, 69-77.
71. Spector, S.A., McKinley, G.F., Lalezari, J.P., Samo, T., Andruczk, R., Follansbee, S., Sparti, B.D., Havlir, D.V., Simpson, G., Buhles, W., Wong, R., Stempien, M., 1996. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N. Engl. J. Med. 334, 1491-1497.
72. Spector, S.A., Merrill, R., Wolf, D., Dankner, W.M., 1992. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J. Clin. Microbiol. 30, 2359-2365.
73. Studies of Ocular Complications of AIDS Research Group, 1996. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch. Opthalmol. 114, 23-33.
74. Tipples, G.A., Ma, M.M., Fischer, K.P., Bain, V.G., Kneteman, N.M., Tyrrell, D.L.J., 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714-717.
75. Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P., Lifson, J.D., Bonhoeffer, S., Nowak, M.A., Hahn, B.H., Saag, M.S., Shaw, G.H., 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
76. Winston, D.J., Ho, W.G., Bartoni, K., Du Mond, C., Ebeling, D.F., Buhles, W.C., 1993. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann. Intern. Med. 118, 179-184.
77. Yamada, G., Takahashi, M., Tsuji, T., Yoshizawa, H., Okamoto, H., 1992. Quantitative HCV RNA and effect of interferon therapy in chronic hepatitis C. Dig. Dis. Sci. 37, 1926-1927.
78. Yerly, S., Kaiser, L., Mermillod, B., Baumberger, C., Hirschel, B., Perrin, L., 1995. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 9, 159-163.
79. Zingman, B.S., 1996. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N. Engl. J. Med. 334, 1674-1675.
80. Zurlo, J.J., O'Neill, D., Polis, M.A., Manischewitz, J., Yarchoan, R., Baseler, M., Lane, H.C., Masur, H., 1993. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann. Intern. Med. 118, 12-17.